

Transparency. Inclusiveness. Global Expertise.

Frequently Asked Questions

on U.S. Proxy Voting Policies and Procedures

(Excluding Compensation-Related Questions)

April 30, 2014

THIS DOCUMENT IS UPDATED FREQUENTLY- CHECK OUR WEBSITE TO ENSURE YOU ARE USING THE LATEST VERSION

Institutional Shareholder Services Inc.

Copyright © 2014 by ISS



U.S. Policy, Procedures, and Proxy Voting Frequently Asked Questions (Excluding Compensation-related Questions)

Updated April 30, 2014

Table of Contents

U.S. RES	EARCH PROCEDURES	6		
1.	Which U.S. companies does ISS cover?	6		
2.	When are proxy analyses issued?	6		
3.	How can a company get a copy of its proxy analysis?	6		
4.	Can a company send the ISS proxy analysis to its shareholders or other parties?	6		
5.	What happens if the proxy analysis contains a factual error?	7		
6.	ISS has issued a negative vote recommendation on an agenda item. What can the company do to reverse it?	7		
7.	How are corrections/changes to proxy analyses communicated and distributed to ISS clients?	7		
8.	How close to the meeting can ISS issue a proxy alert and vote recommendation change?	7		
	MENT WITH U.S. RESEARCH			
9.	With whom does U.S. Research engage?			
10.	Can a company discuss its proxy, once filed, with the analyst?			
Drafts of 11.	f Proxy Analyses Can my company review the ISS analysis prior to publication?			
12.	My company was recently added to the S&P 500. Are we eligible for the draft review process?			
QUESTIC	DNS ON ISS PROXY VOTING GUIDELINES-GENERAL	9		
13.	Whom should I contact with questions on U.S. policies?	9		
14.	What can ISS tell us and not tell us about policies?	9		
15.	What policy does ISS apply to companies that list on a U.S. stock exchange but are not incorporated in the U.S. What about other "cross-market" companies?			
QUESTIC	ONS ON SPECIFIC ISS PROXY VOTING GUIDELINES/POLICIES	10		
Audit-Re	elated			
16.	Why did ISS put the "Tax Fees" under "Other Fees"?			
17.	What disclosure is needed so that ISS will not add Tax Fees to Other Fees?	10		
18.	What is ISS' definition of "material restatements"?	10		
19.	What does ISS consider as non-timely filings?	11		
BOARD (OF DIRECTORS	11		
_	n Director Nominees in Uncontested Elections			
	ıntabilityified Board Structure:			
20	When does ISS apply the classified hoard structure policy?	11		



Poiso	n Pills	11		
21.	What modification must be made to a pill that has a dead hand provision to address an ISS withhold recommendation against all nominees for this issue?	11		
22.	What modification must be made to a pill that has a slow hand (modified dead hand) provision?	11		
23.	What if the pill with a dead hand or slow-hand was approved by the public shareholders?	11		
24.	After what date does the policy regarding adoption or renewal of non-shareholder-approved pills apply?	12		
25.	Why does ISS review annually-elected boards and classified boards differently when they have adopted and continue to hold a poison pill without shareholder approval?	12		
26.	What if a company adopts a poison pill before it is public?	12		
27.	7. What commitment language is ISS looking for concerning putting the poison pill to a binding shareholder vo			
Defin	ition of "Shares Cast"	12		
28.	How does ISS calculate "majority of votes cast"?	12		
Gove	rnance Failures	12		
29.	An executive has hedged company stock. How does ISS view such practice?	12		
30.	How does ISS define a significant level of pledging of company stock?	13		
31.	An executive has pledged a significant amount of company stock as collateral. What is the potential impact of election of directors?			
32.	Should an executive or director who has pledged a significant amount of company stock immediately dispose unwind the position in order to potentially mitigate a negative vote recommendation?			
33.	How would ISS view a board's adoption of a bylaw that disqualifies any director nominee who receives third-party compensation ("director qualification bylaw"), without putting such a bylaw to a shareholder vote?			
34.	If a board puts such a director qualification bylaw to a shareholder vote, will ISS recommend in favor of the proposed bylaw?	14		
35.	How would ISS evaluate director nominees with third-party compensatory arrangements in a proxy contest?			
	nsivenessrity-supported Shareholder Proposals			
36.	What does ISS consider as "responsive" to majority-supported shareholder proposals?	14		
37.	What would constitute a clearly insufficient response to a majority-supported shareholder proposal?	15		
38.	Does ISS consider partial implementation of shareholder proposals more than in the past?	15		
39.	Does the board's recommendation on a management proposal in response to a majority-supported shareho proposal matter?			
40.	Declassify the Board Proposals: If the majority supported shareholder proposal specifies declassification in or year, is a phased-in transition over the next three years sufficient implementation?			
41.	Independent Chair Proposals: is there any action short of appointing an independent chair that would be considered sufficient?	16		
42.	Shareholder proposals on Majority Vote Standards: Is adoption of a "majority vote policy" considered sufficient?	16		
43.	Right for shareholders to call special meetings: If the shareholder proposal specifies an ownership threshold 10 percent, but the company implements a higher threshold, or requires that one shareholder must hold the amount, is that sufficient?	at		



44.	considered acceptable?	16
45.	Right for shareholders to act by written consent: What limitations are generally acceptable?	16
46.	Reducing super-majority vote requirements on charter/bylaw amendments: If the proposal calls for red the vote requirement on charter/bylaw amendments to a majority of shares cast, and the company rec for most provisions, but not all, is that considered sufficient?	
47.	Reducing super-majority vote requirements: If a shareholder proposal calls for reducing requirement to a majority of shares cast, and the company reduces the level to majority of shares outstanding rather than sl cast, is that considered sufficient?	
48.	What if a shareholder proposal is antithetical to the rights of shareholders?	17
Direct	or(s) Receives Less than 50 percent of Shares Cast	18
49.	What happens if a director received less than a majority (50 percent) of votes cast in the previous year?	18
	or Independence mination of Independence	
50.	In the proxy analysis, why did ISS classify a director as an "affiliated outsider"?	18
51.	How does ISS determine whether the board of a U.S. issuer considers a director to be non-independent?	18
Overa	ll Board Independence	18
52.	When ISS looks at whether a board is "majority independent," whose definition of independence are you us	_
53.	What if the board is 50 percent independent outsiders and 50 percent insiders/affiliated outsiders?	18
54.	What public commitment can a company make concerning adding an independent director (and thus making the board majority independent)?	_
Comm	nittee Independence	19
55.	Are non-voting, "ex-officio" members of committees considered as regular members of committees?	19
56.	What steps can a company take to change a vote recommendation on an affiliated outside director serving key committee?	
57.	What disclosure can a company make concerning a non-independent director stepping off a committee?	19
58.	What disclosure can a company make concerning the discontinuation of the purchase of services from an affiliated director's firm, thus making the director independent?	19
Profes	ssional vs. Transactional Relationships	19
59.	How does the definition of affiliation differ in ISS' standards for professional vs. transactional relationships?	· 19
60.	Are insurance services considered professional or transactional?	19
61.	Are information technology services considered professional or transactional?	20
62.	Are marketing services considered professional or transactional?	20
63.	Are educational services considered professional or transactional?	20
64.	Are lobbying services considered professional or transactional?	20
65.	Are executive search services considered professional or transactional?	20
66.	Are property management and real estate services considered professional or transactional?	20
67.	What happens when the company provides professional services to the director or an entity associated wit	h the



68.	How does ISS assess the terms of voting agreements or "standstill" agreements that arise from issuers' settlements with dissenting shareholders?	
Comp	osition	21
Atter	ndance	21
69.	What are the disclosure requirements on director attendance?	21
70.	What if the company is not listed on an exchange – what attendance disclosure is needed?	21
71.	What if there is no attendance disclosure?	21
Overl	boarded Directors	21
72.	What boards does ISS count when looking to see if a director is overboarded?	21
73.	How are subsidiaries of a publicly-traded company counted?	21
74.	What vote recommendations will an overboarded CEO received from ISS?	21
75.	Is the CEO of a private company subject to the policy on overboarded CEOs?	22
76.	Does the overboarded CEO policy apply to an interim CEO?	22
77.	Does ISS take into account if a director is transitioning off one board soon?	22
SHAREH	OLDER RIGHTS & DEFENSES	22
78.	Poison pills: What features of a qualifying offer clause are considered to strengthen its effectiveness and vertices are considered to weaken its effectiveness?	what
CAPITAL	/RESTRUCTURING	2 3
79.	Under the Capital Structure Framework, what are ISS' allowable increases?	
80.	Are my company's one- and three-year TSRs in the bottom 10 percent of the U.S. market?	23
81.	When does ISS deem a risk of non-approval to be "specific and severe"?	23
82.	When will an issuer's past use of shares drive vote recommendations?	23
83.	What disclosure is required to "declaw" preferred stock?	24
SOCIAL/	ENVIRONMENTAL ISSUES	24
Lobbying	g Proposals	24
84.	What does ISS look for when reviewing disclosure of a company's lobbying activity board oversight?	24
85.	What does ISS look for when reviewing a company's indirect lobbying expenditures?	24
86.	What else does ISS consider when reviewing lobbying-related proposals?	24



U.S. Research Procedures

1. Which U.S. companies does ISS cover?

The U.S. research team generally provides proxy analyses and voting recommendations for common shareholder meetings of publicly traded U.S. companies that are held in our institutional investor clients' portfolios, including all in the S&P 1500 and Russell indexes. This generally includes corporate actions for common equity holders, such as written consents and bankruptcies. We cover investment companies (including open-end funds, closed-end funds, exchange-traded funds, and unit investment trusts), limited partnerships ("LPs"), master limited partnerships ("MLPs"), limited liability companies ("LLCs"), and business development companies. ISS reviews its universe of coverage on an annual basis, and the coverage is subject to change based on client need and industry trends.

The US research team also produces, for subscribing clients, research and recommendations for fixed income meetings, and meetings of certain preferred securities, including Auction Rate Preferred Securities ("ARPS") and Variable Rate Municipal Term Preferred securities ("VMTPs").

The U.S. research team also covers companies incorporated in non-U.S. countries if they file Def14As, 10-Qs, and 10-Ks, and are thus considered domestic filers by the SEC.

2. When are proxy analyses issued?

U.S. proxy analyses are generally issued 13-25 calendar days before the shareholder meeting. The timing will depend on: the volume of meetings requiring coverage (e.g., during the U.S. proxy season of February to early June, delivery is closer to 13 days); complexity of the proxy and agenda items; contentiousness of the issues; engagement required; and how close to the meeting the proxy materials were issued. Proxy contest or contested merger analyses are often issued closer to the meeting than these general guidelines.

3. How can a company get a copy of its proxy analysis?

All issuers can access the proxy analyses published by ISS on their companies without charge by accessing the Governance Analytics platform at https://ga.isscorporateservices.com. This platform also enables them without charge to verify the governance data collected for ISS' governance rating/scoring products. This is the best way to ensure timely receipt of the analysis, as an email notification is sent as soon as a new proxy analysis on the company is published. To obtain a login and password to Governance Analytics, please call 301-556-0570 or email support@isscorporateservices.com. All requests for logins or login assistance will typically be responded to within one business day.

Significant time and resources were spent in creating the reports available on the platform and these reports are provided to issuers as a courtesy, subject to the following conditions: (i) the reports are only for the company's internal use by employees of the company, and (ii) the company is expressly prohibited from sharing the reports, profiles or login credentials with any external parties (including but not limited to any external advisors retained by the company such as a law firm, proxy solicitor or compensation consultant) or sharing the user id and password to the platform with any external parties. Please note that this restriction on sharing of reports with outside advisors does not apply to draft reports being reviewed by the company; the restrictions on sharing of drafts are detailed in the letter accompanying the draft.

For other parties who wish to purchase a proxy analysis, please contact our Sales group.

4. Can a company send the ISS proxy analysis to its shareholders or other parties?

No. The information contained in any ISS Proxy Analysis or Proxy Alert may not be republished, broadcast, or redistributed without the prior written consent of ISS.



5. What happens if the proxy analysis contains a factual error?

ISS strives to be as accurate as possible in our research and publications. Please check our Policy Guidelines and the FAQs concerning the issue; it generally is a matter of policy application rather than an error. If you do believe a report contains an error, please notify us as soon as possible at the Research Helpdesk (301-556-0576). If we agree that there is a material change required, we issue a "Proxy Alert" to our clients.

6. ISS has issued a negative vote recommendation on an agenda item. What can the company do to reverse it?

See the FAQs related to the agenda item. (Please note that compensation- related agenda items are covered in a separate FAQ document than this one.) Relevant FAQs provide the <u>minimum</u> disclosures needed to address concerns raised in an analysis.

This additional information must be publicly disclosed for ISS to respond: either in a filing with the SEC, or, if the company is not an SEC filer, a press release will substitute. The language filed does not need to follow the examples exactly; however, these examples specify the points that need to be covered in the disclosure, which may be phrased as each issuer sees fit. Although these types of remedial actions may be accepted by ISS as sufficient solutions to the underlying issues, there may be circumstances, such as egregious actions, in which the indicated actions would not result in a vote recommendation change. Therefore, these are not guarantees of positive vote recommendations or reversals of negative vote recommendations.

ISS will, in its sole discretion, determine if new or materially changed publicly available information warrants an update to our analysis consistent with our policy. Note that ISS does not proactively contact issuers seeking remediation of problematic governance practices; the onus is on issuers to take action in the best interests of their shareholders.

Please also note that ISS does not review all documents as they are filed on Edgar. Companies should notify us when they have filed additional information relevant to a meeting if it is prior to the meeting date – please send a link to the filing to the Research Helpdesk.

7. How are corrections/changes to proxy analyses communicated and distributed to ISS clients?

ISS sends "Proxy Alerts" to communicate corrections, updates, and vote recommendation changes to our clients. A proxy alert is structured as an overlay to the original analysis; the first few pages show the updated information and any related vote recommendation change, but the original analysis lies underneath, and will continue to reflect the original information. This allows our clients to see the original report and the changes in one document. Any subsequent alerts will be layered on top of the previous alert(s).

Proxy alerts are distributed to our institutional clients the same way our regular proxy analyses are distributed – through our ProxyExchange platform. Most clients give us their portfolio holdings so we can "attach" them to the company meeting. They will then receive through this platform all analyses and alerts on companies that are in their portfolios or that they have requested. Thus, the same clients who received the original analysis will receive the proxy alert.

8. How close to the meeting can ISS issue a proxy alert and vote recommendation change?

To ensure that all our institutional clients are able to review a change in our vote recommendation and act upon this information if they so choose, we generally will not issue a change to a vote recommendation closer than **5** business days before the meeting. This means that if a company is filing additional information with the SEC (or issuing a press release for non-SEC filers), ISS must be informed of this filing at least 5 business days before the meeting. For example, for a Thursday meeting, we will need to know of the filing no closer to the meeting than 5 p.m. Eastern the Thursday before (assuming no national holiday during that week.) Please send the link to the filing to the Research Helpdesk. A voicemail left concerning the filing is not sufficient.



Any new information received closer than 5 business days before the meeting will be discussed in an informational alert if it is deemed to be material to the analysis, even if there is no change to ISS' voting recommendations.

Under highly extraordinary circumstances, ISS may issue an alert to change a vote recommendation closer than 5 business days before the meeting only under highly extraordinary circumstances.

Engagement with U.S. Research

Please see the general Engagement Section of our website for more details.

9. With whom does U.S. Research engage?

ISS analysts engage with shareholders, corporate issuers, dissident shareholders, solicitors, sponsors of shareholder proposals, and other external parties when we believe that doing so will result in a higher quality research report for our clients. The purpose of such engagement is for ISS to obtain, or communicate, clarification about governance and voting issues, in order to ensure that our research and policy-driven recommendations are based on the most comprehensive and accurate information available. Sometimes these conversations are initiated by ISS, and sometimes they are initiated by the issuer or shareholder.

In contested situations, we consider it an important step in our research process to engage with both sides. (Occasionally, one side is unable or unwilling to speak with us.) Conversations are normally held via teleconference; ISS conducts inperson meetings only in the case of very controversial issues. Please contact Marc Goldstein (301-556-0447) if your company is facing a contentious situation (such as a proxy contest, or a "Vote-no" campaign), or you are a third party representing a company in a contentious situation, so conversations can be set up as soon as possible.

Once ISS has issued a recommendation, we will not engage with issuers or their representatives whose purpose is solely to lobby for a favorable vote recommendation.

10. Can a company discuss its proxy, once filed, with the analyst?

For non-contentious situations, it is the analysts' discretion whether engagement with the company is necessary or appropriate, and they generally only do so to clarify points on which they have questions. Further, ISS analyses are based only on publicly disclosed information, so all the information needed for shareholders and analysts to make their decisions should be in the proxy.

Providing the Research Helpdesk with company contact information is very useful, so that, if the analysts have questions, they can quickly contact the company.

If there are particular points you want to be sure the analysts are aware of (for example, information relevant to an equity compensation plan that may be in a footnote, or corporate governance changes the company has undertaken), please send an email to the Research Helpdesk with the points outlined and the proxy page or other source noted – it will be put in the appropriate meeting folder so the analysts can review it when they are ready to do so.

Please note that any information presented as factual must be public, in the proxy statement or other filing, in order to be included in our research reports. To maintain the integrity of our <u>firewall</u>, the Research Helpdesk staff will remove all references to the purchase of Corporate Services (ICS) products and services before forwarding emails to the Research analysts.



Drafts of Proxy Analyses

11. Can my company review the ISS analysis prior to publication?

In the United States, only companies in the S&P 500 index will receive a draft report for fact-checking; however, within this group, ISS does not normally allow preliminary reviews of any analysis relating to any special meeting or any meeting where the agenda includes a merger or acquisition proposal, proxy fight, or any item that ISS, in its sole discretion, considers to be of a controversial nature (for example, a "vote no" campaign). This policy is intended to ensure the independence of our process and recommendations.

Drafts are sent only to S&P500 companies who elect to receive them, and sign up to do so in advance of proxy season. Please sign up using our <u>online form</u> (http://www.issgovernance.com/USDraftReviewConfirmation)

12. My company was recently added to the S&P 500. Are we eligible for the draft review process?

For annual meetings occurring during U.S. proxy season (February through June), ISS uses the S&P 500 component list as of January 31. Following June 30 of each year, ISS updates its list to reflect changes to the index in real time. Companies added to the index after January 31 that hold their meetings prior to June 30 will be eligible for a draft review beginning the following year.

Questions on ISS Proxy Voting Guidelines-General

13. Whom should I contact with questions on U.S. policies?

Please contact the Research Helpdesk: USResearch@issgovernance.com, 301-556-0576, with your questions.

14. What can ISS tell us and not tell us about policies?

ISS will try to clarify policy questions as much as possible. We cannot answer questions about hypothetical scenarios, and we cannot give definitive answers on how we will recommend on proxy items before we analyze all relevant facts and circumstances as presented in the proxy. If it is a question we cannot answer, we will let you know. If the question is of widespread interest, we will add it to these FAQs.

15. What policy does ISS apply to companies that list on a U.S. stock exchange but are not incorporated in the U.S.? What about other "cross-market" companies?

Like the SEC, ISS distinguishes two types of companies that list but are not incorporated in the U.S.:

- U.S. Domestic Issuers -- which have a majority of shareholders in the U.S. and meet other criteria, as determined by the SEC, and are subject to the same disclosure and listing standards as U.S. incorporated companies are generally covered under standard U.S. policy guidelines.
- Foreign Private Issuers (FPIs) which do not meet the Domestic Issuer criteria and are exempt from most disclosure requirements (e.g., they do not file 10-K or DEF14A reports) and listing standards (e.g., for required levels of board and committee independence) are covered under a combination of policy guidelines:
 - 1. FPI Guidelines, which apply certain minimum independence and disclosure standards in the evaluation of key proxy ballot items, such as the election of directors and approval of financial reports, and
 - 2. For other issues, guidelines for the market that is responsible for, or most relevant to, the item on the ballot.

In all cases – including with respect to other companies with cross-market features that may lead to ballot items related to multiple markets -- items that are on the ballot solely due to the requirements of another market (listing, incorporation, or national code) may be evaluated under the policy of the relevant market, regardless of the "assigned" market coverage.



Note that a number of FPIs incorporate in U.S. off-shore "tax haven" markets, such as Bermuda, the Bahamas, Cayman Islands, and Marshall Islands. These companies may list in the U.S. and or other markets such as Hong Kong or Singapore, in which cases ISS assigns a primary coverage market and applies policy as above.

Questions on Specific ISS Proxy Voting Guidelines/Policies

Audit-Related

16. Why did ISS put the "Tax Fees" under "Other Fees"?

ISS recognizes that certain tax-related services, e.g. tax compliance and preparation, are most economically provided by the audit firm. Tax compliance and preparation include the preparation of original and amended tax returns, refund claims, and tax payment planning. However, other services in the tax category, e.g. tax advice, planning, or consulting fall more into a consulting category. Therefore, these fees are separated from the tax compliance/preparation category and are added to the Non-audit fees. If the breakout of tax compliance/preparation fees cannot be determined, all tax fees are added to "Other" fees.

17. What disclosure is needed so that ISS will not add Tax Fees to Other Fees?

Provide as a footnote to the audit fees table a breakout of the tax fees: those related to tax compliance and preparation fees, i.e. the preparation of original and amended tax returns, refund claims, and tax payment planning, vs. those related to all other services in the tax category, such as tax advice, planning, or consulting.

18. What is ISS' definition of "material restatements"?

When determining if a company has a material restatement, ISS' guidelines are:

- Has the company restated financial results for any period during the past 24 months (this refers to when the company restated its financial statements, not the period restated);
- Did the restatement cause material changes (whether positive or negative) to the financial statements? Possible exceptions to the rule would be industry-specific issues, such as poor inventory control in a manufacturing/industrial company or poor asset valuations for financial institutions;
- Include announced restatements that are being made to correct material misstatements of previously reported financial information;
- Exclude announcements involving stock splits, changes in accounting principles (rule changes), and other
 restatements that were not made to correct mistakes in the application of accounting standards;
- Revisions and restatements linked to a material weakness are considered material.

Some examples of restatements that are generally excluded:

- Those resulting from mergers and acquisitions;
- Discontinued operations;
- Stock splits, issuance of stock dividends;
- Currency-related issues (for example, converting from Japanese yen to U.S. dollars);
- Changes in business segment definitions;
- Changes due to transfers of management;
- Changes made for presentation purposes;
- General accounting changes under generally accepted accounting principles (GAAP); and
- Litigation settlements.



19. What does ISS consider as non-timely filings?

ISS considers any NT filing as evidence of non-timely filings.

Board of Directors

Voting on Director Nominees in Uncontested Elections

Accountability

Classified Board Structure:

20. When does ISS apply the classified board structure policy?

The classified board structure policy is: if a director responsible for a governance problem is not up for election due to a classified board, ISS will recommend withhold or against votes on all appropriate nominees. This policy is generally not applied if the director in question has a governance issue related only to him or herself, (e.g., poor attendance, overboarded, or is an Affiliated Outside Director serving on a key committee), unless the issue is considered egregious. It is typically applied when ISS would normally recommend withhold on all the members of a committee – e.g., the compensation committee for problematic pay practices or a pay for performance disconnect, or the audit committee for continued material weaknesses in internal controls – and no one on the committee is a nominee on the ballot. The rationale is that a classified board further entrenches management and prevents shareholders from holding the responsible individuals accountable.

Poison Pills

21. What modification must be made to a pill that has a dead hand provision to address an ISS withhold recommendation against all nominees for this issue?

The amendment would need to eliminate all requirements in the Rights Agreement that actions, approvals, and determinations taken or made by the company's board of directors be taken or made by a majority of the "Continuing Directors" (sometimes also referred to as the disinterested directors).

22. What modification must be made to a pill that has a slow hand (modified dead hand) provision? Sample language:

"The Agreement is hereby amended to remove the following sentence from the [# of paragraph]: The Rights generally may not be redeemed for one hundred eighty (180) days following a change in a majority of the Board as a result of a proxy contest."

23. What if the pill with a dead hand or slow-hand was approved by the public shareholders?

Even if a pill has features that cause ISS to recommend against the adoption of the pill, if the pill is approved by shareholders (with a broad shareholder base, not a controlled company, not prior to IPO, etc.), then ISS will not recommend against the board. For example: Marina Biotech (MRNA) adopted a poison pill in 2010 that has a slow-hand, but it was approved by their broad shareholder base. ISS is not recommending against the board, as the pill was approved by shareholders.



24. After what date does the policy regarding adoption or renewal of non-shareholder-approved pills apply?

ISS' current policy on pill adoptions applies to pills adopted/renewed after the date the policy was announced, which was Nov 19, 2009. The previous policy, for pills adopted after Dec 7, 2004, was to only recommend against the board only once for not putting it to a vote.

25. Why does ISS review annually-elected boards and classified boards differently when they have adopted and continue to hold a poison pill without shareholder approval?

There are 3 principles at work in this policy: 1) All poison pills should be put to a shareholder vote; 2) the term of a poison pill should be no longer than 3 years, so shareholders should be voting on an existing pill at least every 3 years; and 3) all board members should be held accountable for the adoption of the pill and for not putting the pill to a shareholder vote. So, for an annually-elected board, where all members can be held accountable at once; over the life of the pill, ISS recommends withhold every 3 years based upon the frequency we would have expected the pill to be brought to a shareholder vote and it wasn't. For a classified board, it takes 3 years just to hold all board members accountable, and then the 3- year cycle at which the pill should have been put to a vote starts again, thus, the recommendations against all nominees each year.

26. What if a company adopts a poison pill before it is public?

In the case of an newly public company, ISS will recommend withhold on the entire board if the pill is not put to a vote at the first annual meeting of public shareholders or if the company does not commit to putting the pill to a shareholder vote within 12 months following the IPO. In the following years, as long as the pill exists and is not put to a shareholder vote, the withholds recommendations will continue as described in the FAQ above depending on whether the board is annually elected or classified.

27. What commitment language is ISS looking for concerning putting the poison pill to a binding shareholder vote? Sample language:

"On [date] the Board of Directors determined that it will either (i) include in its proxy statement for the Company's [next year's] Annual Meeting of Stockholders a proposal (the "Rights Plan Proposal") soliciting stockholder approval of the Company's existing stockholder rights plan, or (ii) repeal the stockholder rights plan prior to the [next year's] Annual Meeting. In the event that the Company elects to include the Rights Plan Proposal in the proxy statement, and the Company does not receive the affirmative vote of the holders of [voting requirement], then the Company will promptly take action to repeal the stockholder rights plan."

Definition of "Shares Cast"

28. How does ISS calculate "majority of votes cast"?

For policies that utilize "shares cast" as the measurement (e.g. management say-on-pay proposals, majority-supported shareholder proposals, and majority withholds on directors), ISS uses: For/ (For + Against). Abstentions are not counted. The base the issuer uses to determine if a proposal passed is not used, as doing so would result in an inconsistent basis for looking at voting outcomes across companies.

Governance Failures

29. An executive has hedged company stock. How does ISS view such practice?

Hedging is a strategy to offset or reduce the risk of price fluctuations for an asset or equity. Stock-based compensation or open market purchases of company stock should serve to align executives' or directors' interests with shareholders. Therefore, hedging of company stock through covered call, collar or other derivative transactions sever the ultimate



alignment with shareholders' interests. Any amount of hedging will be considered a problematic practice warranting a negative vote recommendation against appropriate board members.

30. How does ISS define a significant level of pledging of company stock?

ISS' view is that <u>any</u> amount of pledged stock is not a responsible use of company equity. A sudden forced sale of significant company stock may negatively impact the company's stock price, and may also violate insider trading policies. In addition, share pledging may be utilized as part of hedging or monetization strategies that would potentially immunize an executive against economic exposure to the company's stock, even while maintaining voting rights. A significant level of pledged company stock is determined on a case-by-case basis by measuring the aggregate pledged shares in terms of common shares outstanding or market value or trading volume.

31. An executive has pledged a significant amount of company stock as collateral. What is the potential impact on election of directors?

In determining vote recommendations for the election of directors of companies who currently have executives or directors with pledged company stock, the following factors will be considered:

- Presence of anti-pledging policy that prohibits future pledging activity in the companies' proxy statement;
- Magnitude of aggregate pledged shares in terms of total common shares outstanding or market value or trading volume;
- Disclosure of progress or lack thereof in reducing the magnitude of aggregate pledged shares over time;
- Disclosure in the proxy statement that shares subject to stock ownership and holding requirements do not include pledged company stock; and
- Any other relevant factors.

If the company discloses a pledged amount, we will first consider the significance of the pledge. If we determine that it is at a level that raises significant risks for shareholders -- or, in some cases, if we determine that the incidence or significance of pledging at the company is increasing -- we may recommend against board members considered accountable for the company's policy on pledging (or lack thereof). But, if the company indicates that they have a policy that prohibits future new pledging and/or that they are encouraging executives/directors to unwind current transactions, these would be viewed as positive factors that could mitigate a negative recommendation at the current meeting.

32. Should an executive or director who has pledged a significant amount of company stock immediately dispose or unwind the position in order to potentially mitigate a negative vote recommendation?

An executive or director who has pledged a significant amount of company stock should act responsibly and not jeopardize shareholders' interests. The aggregate pledged shares should be reduced over time, and the company should adopt a policy that prohibits future pledging activity, and disclose that in its proxy statement. Note that if the individual's aggregate pledged shares were to increase over time, a negative vote recommendation may be warranted despite the company's adoption of an anti-pledging policy.

33. How would ISS view a board's adoption of a bylaw that disqualifies any director nominee who receives third-party compensation ("director qualification bylaw"), without putting such a bylaw to a shareholder vote?

The adoption of restrictive director qualification bylaws without shareholder approval may be considered a material failure of governance because the ability to elect directors is a fundamental shareholder right. Bylaws that preclude shareholders from voting on otherwise qualified candidates unnecessarily infringe on this core franchise right. Consistent with ISS' "Governance Failures" policy, we may, in such circumstances, recommend a vote against or withhold from director nominees for material failures of governance, stewardship, risk oversight, or fiduciary responsibilities.



However, ISS has not recommended voting against directors and boards at companies which have adopted bylaws precluding from board service those director nominees who fail to disclose third-party compensatory payments. Such provisions may provide greater transparency for shareholders, and allow for better-informed voting decisions.

34. If a board puts such a director qualification bylaw to a shareholder vote, will ISS recommend in favor of the proposed bylaw?

ISS will apply a case-by-case analytical framework, taking into consideration among other factors the board's rationale for proposing the bylaw, whether the proposed bylaw materially impairs, and/or delivers any off-setting improvements in shareholder rights, and any market-specific practices or views on the underlying issue.

35. How would ISS evaluate director nominees with third-party compensatory arrangements in a proxy contest?

Compensation arrangements with director nominees are among the factors ISS considers in our case-by-case analysis of proxy contests. Further discussion of ISS' analytic framework for contested elections is available in the U.S. and Canadian Summary Guidelines.

Responsiveness

Majority-supported Shareholder Proposals

36. What does ISS consider as "responsive" to majority-supported shareholder proposals?

Acting on a shareholder proposal will generally mean either full implementation of the proposal or, if the matter requires a vote by shareholders, a management proposal on the next annual ballot to implement the proposal. Responses that involve less than full implementation will be considered on a case-by-case basis, taking into account:

- Disclosed outreach efforts by the board to shareholders in the wake of the vote;
- Rationale provided in the proxy statement for the level of implementation;
- The subject matter of the proposal;
- The level of support for and opposition to the resolution in past meetings;
- Actions taken by the board in response to the majority vote and its engagement with shareholders;
- The continuation of the underlying issue as a voting item on the ballot (as either shareholder or management proposals); and
- Other factors as appropriate.

These factors are further described below:

Disclosed outreach efforts by the board to shareholders in the wake of the vote:

Key to any partial implementation of a majority supported shareholder proposal is outreach by the board to their significant shareholders who supported the proposal to understand why they supported it and what they are looking for the board to do in response. The "ask" of the proposal may not directly reflect shareholders' concerns but instead may have been the vehicle most-readily available for them to express their concerns. For example, shareholders may be more interested in a stronger right to a special meeting, rather than the written consent right proposed. Or, they may want a more empowered lead director position in lieu of an independent chair.

While outreach to the proponent is important, it was a majority of shares that voted for the proposal. Therefore, the company should reach out beyond the proponent to its large shareholders to understand their goals in the support of the proposal.

Rationale provided in the proxy for the level of implementation:



The vast majority of shareholder proposals are precatory; they are not binding, and the board exercises its discretion to respond in a manner that it believes is in the best interest of the company. When a majority of shares or a substantial minority, are cast in support of a proposal, the company should clearly disclose its response and explain the board's rationale for the actions it has taken in the following year's proxy statement.

The subject matter of the proposal:

Some matters are straightforward, almost binary decisions, and garner a strong consensus among institutional investors, such as:

Declassification proposals—either a board is classified, or it is annually elected. While shareholders may defer to the board's discretion as to timing of the declassification, there is generally no other action acceptable. Majority vote standard—either a board has a plurality or a majority vote standard in uncontested elections. There is a

consensus that a true majority vote standard is the board response required, and not just the adoption of a director resignation policy while maintaining a plurality vote standard.

Other items are more nuanced and allow for a broader range of implementation, such as the right to call a special meeting, the right for shareholders to be able to act by written consent, or proposals seeking an independent board chair. Please see FAQs below on these items for more details.

37. What would constitute a clearly insufficient response to a majority-supported shareholder proposal?

Clear examples of non-responsiveness by the board would include: no acknowledgement at all in the proxy statement that shareholders supported the proposal; dismissal of the proposal with no reasons given; or actions taken to prevent future shareholder input on the matter altogether.

38. Does ISS consider partial implementation of shareholder proposals more than in the past?

Yes, our analysis is case-by-case on partial implementation. Under previous policy, it was very difficult for shareholder proposals to reach the hurdles of two years of votes cast, as companies could prevent the reappearance of the proposal on the ballot within the 3-year period (e.g. through the SEC's no-action process). Since it was difficult for shareholders to achieve this result, once it was achieved, it was reasonable to expect full implementation of the proposal. Under current ISS policy, the shareholder approval hurdle has been lowered to one year of votes cast; as such, the "implementation hurdle" by which the company's response is evaluated is also more flexible. If shareholder proponents are unhappy with a company's partial response, the expectation is that they can re-file another shareholder proposal in the future.

39. Does the board's recommendation on a management proposal in response to a majority-supported shareholder proposal matter?

In general, the proposal should have a board recommendation of FOR. A recommendation other than a FOR, (e.g." None" or "Against") will generally not be considered as sufficient action taken. The level of support necessary to implement the proposal (e.g., a supermajority of shares outstanding) will be a consideration in evaluating the role of the board's recommendation.

40. Declassify the Board Proposals: If the majority supported shareholder proposal specifies declassification in one year, is a phased-in transition over the next three years sufficient implementation?

Although a proponent may request immediate declassification, our institutional investor clients have indicated that a phased-in declassification that allows for directors to fulfill their full elected terms is generally acceptable. However, delays to the start of the phase-in of declassification (such as Ryder Systems' 2013 delay of the phase-in to 2016-2018) should be vetted with shareholders and the rationale for the long delay included in the proxy statement.



41. Independent Chair Proposals: is there any action short of appointing an independent chair that would be considered sufficient?

Full implementation would consist of separating the chair and CEO positions, with an independent director filling the role of chair. A policy that the company will adopt this structure upon the resignation of the current CEO would also be considered responsive.

Partial responses will be evaluated on a case-by-case basis, depending on the disclosure of shareholder input obtained through the company's outreach, the board's rationale, and the facts and circumstances of the case. There are many factors that can cause investors to support such proposals, without necessarily demanding an independent chair immediately. For example, through their outreach, a company may learn that shareholders are concerned about the lack of a lead director, weaknesses in the lead director's responsibilities, or the choice of lead director. In such a case, creating or strengthening a robust lead director position may be considered a sufficient response, assuming no other factors are involved. If the company already has a robust lead director position, then the company's outreach to shareholders to discover the causes of the majority vote and subsequent actions to address the issue will be reviewed accordingly.

42. Shareholder proposals on Majority Vote Standards: Is adoption of a "majority vote policy" considered sufficient?

In general, adoption of a director resignation policy (sometimes called a majority vote policy) in lieu of a true majority vote standard is not considered a sufficient response. The "vote standard" is the standard which determines whether the director is an elected director: under a plurality vote standard, a director need only receive one vote to be "elected." A majority vote standard requires a director to receive support from a majority of the shares cast to be elected: if not achieved, and a new nominee would not be able to join the board; if the nominee is a continuing director, his or her legal status is a "holdover" director, not an elected director. The vote standard is usually embedded in the company's charter or bylaws, and is included in the proxy statement. A "majority vote policy" is a confusing term sometimes used to describe a director resignation policy, which is the post-election process to be followed if a director does not receive a majority of votes cast. Such resignation policies are usually found in a company's corporate governance guidelines, and can accompany either a majority or a plurality vote standard. Such a policy alone is not the same as a true majority vote standard.

43. Right for shareholders to call special meetings: If the shareholder proposal specifies an ownership threshold of 10 percent, but the company implements a higher threshold, or requires that one shareholder must hold that amount, is that sufficient?

According to our 2010 policy survey, 56 percent of institutional clients did not accept a higher threshold as a sufficient response. However, if the company's outreach to its shareholders finds a different threshold acceptable to them, and the company disclosed these results in its proxy statement, along with the board's rationale for the threshold chosen, this will be fully considered on a case-by-case basis. The ownership structure of the company will also be a factor in ISS' consideration.

44. Right for shareholders to call special meetings: What types of parameters set on the right are generally considered acceptable?

Restrictions on agenda items are generally seen as negating the right to call a special meeting; 71 percent of institutional investor respondents to our 2010 policy survey said this was not sufficient implementation. The more common type of agenda restriction seen is to exclude any agenda items that were on the previous annual meeting agenda, or will be on the upcoming annual meeting agenda. Such a prohibition would prevent shareholders from calling a special meeting to elect a dissident slate, as the annual meeting agendas would include election of directors on the ballot.

Reasonable limitations on the timing and number per year of special meetings are generally acceptable.

45. Right for shareholders to act by written consent: What limitations are generally acceptable?

Reasonable restrictions to ensure that the right to act by written consent could not potentially be abused are acceptable. In general, restrictions considered reasonable include:

An ownership threshold of no greater than 10 percent;



- No restrictions on agenda items;
- A total review and solicitation period of no more than 90 days (to include the period of time for the company to set a record date after receiving a shareholder request to do so, and no more than 60 days from the record date for the solicitation process);
- Limits on when written consent may be used of no more than 30 days after a meeting already held or 90 days before a meeting already scheduled to occur; and
- A solicitation requirement that the solicitor must use best efforts to solicit consents from all shareholders.

Restrictions that go beyond these levels are examined in light of the disclosure by the company about its outreach to shareholders, the board's rationale, etc. An example was Amgen, which received majority support on a written consent proposal. It sought feedback from its shareholders, and in 2012 put on the ballot a management proposal discussing the shareholder feedback obtained and the procedural safeguards implemented in response to the feedback. Among these was a 15 percent ownership threshold, the same as their threshold to call special meetings.

46. Reducing super-majority vote requirements on charter/bylaw amendments: If the proposal calls for reducing the vote requirement on charter/bylaw amendments to a majority of shares cast, and the company reduces it for most provisions, but not all, is that considered sufficient?

In general, shareholders would look for all provisions to be reduced to the majority of shares cast. However, exceptions may occur. An example is where the supermajority applies only to a provision that would be antithetical to shareholders' rights, such as the ability to reclassify the board. Disclosure on which items were not reduced, and why, is a key consideration.

47. Reducing super-majority vote requirements: If a shareholder proposal calls for reducing requirement to a majority of shares cast, and the company reduces the level to majority of shares outstanding rather than shares cast, is that considered sufficient?

In general, reducing to the majority of cast is preferable among institutional investors. However, state law may mandate no less than a majority of outstanding shares threshold. The board's rationale and the disclosed outcome of the company's outreach to shareholders are key considerations.

In general, a reduction from a supermajority to a slightly lower supermajority (e.g. 75 percent to 66.7 percent), would not be considered a sufficient response, according to 71 percent of our institutional clients surveyed. However, the company's outreach to shareholders and board's rationale are also considerations.

48. What if a shareholder proposal is antithetical to the rights of shareholders?

Arguing that a proposal that received a majority of shareholder votes is antithetical to shareholders' interests, particularly at a widely held company, is a difficult proposition – it implies that shareholders are not acting in their own best interests. However, there are cases where majority-supported proposals go against the interests of minority shareholders, e.g. at controlled company AMERCO (2007, 2009-2012, subject to Nevada Court decisions on the matters). ISS obviously does not expect that companies will "act" on proposals contrary to the interest of all shareholders, particularly minority shareholders.

Likewise, ISS does not expect a company to act on a proposal invalidated by court rulings or state law. For example, there were majority-supported shareholder proposals on certain bylaw changes at Airgas in 2010 during their proxy fight with Air Products. The Delaware Supreme Court invalidated the bylaw changes; ISS would expect the company to act in accordance with the court rulings.



Director(s) Receives Less than 50 percent of Shares Cast

49. What happens if a director received less than a majority (50 percent) of votes cast in the previous year?

If a director receives a majority of votes withhold/against him or her, ISS considers whether or not the company has addressed the underlying issues that led to the high level of opposition. Disclosed outreach to shareholders and disclosure of the steps taken in response to their findings, are key considerations. ISS may recommend withhold/against individual directors, a committee, or the entire board the following year if all the underlying issue(s) causing the high level of opposition are not addressed.

Director Independence

Determination of Independence

50. In the proxy analysis, why did ISS classify a director as an "affiliated outsider"?

Please look at the "Affiliation Notes" under the Board Profile section of the proxy analysis. This will tell you the nature of the affiliation, and whether it is material under ISS' definitions. The material affiliations are shown in our Proxy Voting Guidelines under the Categorization of Directors table.

51. How does ISS determine whether the board of a U.S. issuer considers a director to be non-independent?

In the US, issuers subject to the reporting requirements of Item 407 of Regulation S-K are not required to explicitly identify their non-independent directors as long as they maintain fully independent Audit, Compensation, and Nominating committees. If a board maintains fully independent committees, it is only required to identify its independent directors, including new nominees, in its proxy or annual report.

In these situations, ISS will generally conclude that if a board does not identify one or more directors as independent, then it does not consider such director(s) to be independent. ISS will also examine all relevant disclosures, including, but not limited to, director bios, related party transactions, committee disclosure, and potentially review the issuer's historical approach to director independence disclosure to determine whether an issuer may have omitted an independent director from its list of independent directors.

It is corporate governance best practice for boards to be transparent to shareholders regarding the independence status of each director. In the context of the aforementioned US disclosure rules, the failure of a board to identify a director as independent will generally be construed to mean that the board does not consider such director to be independent.

Overall Board Independence

52. When ISS looks at whether a board is "majority independent," whose definition of independence are you using? ISS is using our definition of "independent outside director" to determine if the board is majority independent.

53. What if the board is 50 percent independent outsiders and 50 percent insiders/affiliated outsiders?

50 percent is not a majority. ISS would not consider this board majority independent.

54. What public commitment can a company make concerning adding an independent director (and thus making the board majority independent)?

Sample language:



"We are conducting a director search in the exercise of due care for a candidate as soon as practicable following our Annual Meeting of Stockholders. Our new director will not only satisfy the independence requirements under the listing requirements, but will have no material connection to our Company (that is, no material financial, personal, business, or other relationship that a reasonable person could conclude could potentially influence boardroom objectivity) prior to being appointed to the Board. We commit to having this new director in place within no more than six months after the upcoming shareholder meeting."

Committee Independence

55. Are non-voting, "ex-officio" members of committees considered as regular members of committees?

Yes. They are considered the same as any other committee member, with the same expectation of independence.

56. What steps can a company take to change a vote recommendation on an affiliated outside director serving on a key committee?

For ISS to change its vote recommendation, either the director needs to step off the committee, or the material relationship causing the affiliation (e.g. professional relations with a firm associated with the director) would need to be terminated.

57. What disclosure can a company make concerning a non-independent director stepping off a committee? Sample language:

"As of [date no later than the upcoming annual meeting date], [Director Name] will resign as a member of the [Committee]."

58. What disclosure can a company make concerning the discontinuation of the purchase of services from an affiliated director's firm, thus making the director independent?

Sample language:

"Effective [today], the Company will no longer purchase services from the [service provider] as long as [affiliated Director] serves on the Company's Board of Directors."

Please note this disclosure will not change the classification of the director if the fees are sufficient to trigger the look-back period under the company's listing standards. (ISS is not going to classify a director as independent when the board is unable to do so.)

Professional vs. Transactional Relationships

59. How does the definition of affiliation differ in ISS' standards for professional vs. transactional relationships?

Both are derived from the definition of affiliation in NASDAQ Rule 5605—but the affiliation under professional services is more strict: a director (or immediate family member) only has to be an employee of the organization providing the professional service, as opposed to an executive officer in the case of a transactional relationship for him to be considered affiliated.

60. Are insurance services considered professional or transactional?

Insurance services are considered professional services unless the company explains why such services are not advisory. These services are frequently advisory in nature, involve access to sensitive company information, and have a payment structure that could create a conflict of interest. Commissions or fees paid to a director (or to an immediate family member or an entity affiliated with either the director or the immediate family member) are an indication that the relationship is a professional service. The case where a company has an insurance policy with and pays premiums to an entity with which



one of the company's directors is affiliated will be considered a transactional relationship. However, the burden will be on the company to explain why the service is not advisory.

61. Are information technology services considered professional or transactional?

Information technology (IT) services are generally considered professional services unless such services are tech support. Although tech support could be considered advisory in nature, generally the provision of such services is tied to a previous transactional relationship, typically a purchase of hardware or software. The provision of tech support does not involve strategic decision-making or a payment structure which could create a conflict of interest.

62. Are marketing services considered professional or transactional?

Marketing services are considered professional services unless the company explains why such services are not advisory. Certain types of marketing services could reasonably be considered advisory in nature, involving access to sensitive company information or to strategic decision-making, such as: market research, market strategy, branding strategy, and advertising strategy. Other marketing services, such as the sale of promotional materials, sponsorships, or the purchase of advertising, are transactional in nature. However, the burden will be on the company to make the distinction.

63. Are educational services considered professional or transactional?

Educational services are generally considered to be transactional in nature. Educational services are typically not advisory and do not generally involve access to sensitive company information or to strategic decision-making.

64. Are lobbying services considered professional or transactional?

Lobbying services are considered professional services. These services are advisory in nature and have a payment structure that could create a conflict of interest.

65. Are executive search services considered professional or transactional?

Executive search services are generally considered professional services. These services are advisory in nature and have a payment structure that could create a conflict of interest. Lower level employment services may be considered transactional, depending on the disclosure.

66. Are property management and real estate services considered professional or transactional?

Property management and real estate services will generally be considered professional services. These services are advisory in nature and have a payment structure that could create a conflict of interest.

67. What happens when the company provides professional services to the director or an entity associated with the director?

In the case of a company providing a professional service to one of its directors or to an entity with which one of its directors is affiliated, the relationship is considered transactional rather than professional. Since neither the director nor the entity with which the director is affiliated is receiving fees for the service, there is no direct financial tie which could compromise that director's independence.

68. How does ISS assess the terms of voting agreements or "standstill" agreements that arise from issuers' settlements with dissenting shareholders?

In addition to the classification of any directors that the dissident shareholder may have placed on the board pursuant to our Director Independence policy and section 2.15 of our Categorization of Directors table, ISS will examine the terms of the standstill agreement and any other conflicting relationships or related-party transactions and, pursuant to our Board



Accountability policy, may issue negative recommendations affecting the reelection of Nominating Committee members if we deem any terms of or circumstances surrounding the agreement to be egregious.

Composition

Attendance

69. What are the disclosure requirements on director attendance?

For exchange-listed companies, the SEC requires the following disclosure:

Item 407(b) Board meetings and committees; annual meeting attendance. (1) State the total number of meetings of the board of directors (including regularly scheduled and special meetings) which were held during the last full fiscal year. Name each incumbent director who during the last full fiscal year attended fewer than 75 percent of the aggregate of:

- i. The total number of meetings of the board of directors (held during the period for which he has been a director); and
- ii. The total number of meetings held by all committees of the board on which he served (during the periods that he served).

70. What if the company is not listed on an exchange - what attendance disclosure is needed?

Institutional investors expect similar attendance disclosure for non-listed companies as for listed companies.

71. What if there is no attendance disclosure?

Under the regulations, disclosure is <u>only</u> needed if a director attended less than 75 percent of the aggregate of his/her board and committee meetings for the period he/she served. Therefore, no disclosure would mean that all directors met the attendance threshold. Many companies will include in their proxies a positive statement that all directors met the threshold, but it is not required.

Overboarded Directors

72. What boards does ISS count when looking to see if a director is overboarded?

We include: any publicly-traded company (including non-U.S. companies) in ISS' institutional investor clients' portfolios, companies traded on major exchanges even if not in our clients' portfolios, and mutual fund families. We do not include: non-profit organizations, universities, advisory boards, and private companies. Mutual funds are rolled up to mutual fund families, with one family counting as one board. Also, if service on another board is a required duty of the officer (e.g., as part of a joint marketing agreement), that board will not be counted.

73. How are subsidiaries of a publicly-traded company counted?

All subsidiaries with publicly- traded stock are counted as boards in their own right. Subsidiaries that only issue debt are not counted.

74. What vote recommendations will an overboarded CEO received from ISS?

ISS will not recommend withhold/against votes for overboarding at the company where he or she serves as CEO, but may do so at the outside boards.



Special consideration is given where the CEO of a parent company also serves on the boards of the company's publicly traded subsidiaries. ISS will not recommend withhold/against votes for overboarding on the parent company's CEO at the parent company, nor at any subsidiary board with over 50 ownership by the parent. At outside boards and at subsidiaries owned 50 percent or less by the parent, ISS will consider whether withhold/against votes are warranted on a case-by-case basis, considering among other factors:

- Structure of the parent subsidiary relationship (for example, holding company structure);
- Similarity of business lines between the parent and subsidiary;
- Percentage of subsidiary held by the parent company; and
- The total number of boards on which he/she serves.

75. Is the CEO of a private company subject to the policy on overboarded CEOs?

No. This policy is only applied to public-company CEOs.

76. Does the overboarded CEO policy apply to an interim CEO?

No. There is no expectation that a director who steps in as interim CEO to fill the gap should drop his or her other boards for this short-term obligation.

77. Does ISS take into account if a director is transitioning off one board soon?

Yes. If the information is publicly disclosed that a director will be stepping off another board at the next annual meeting of that company to accommodate taking a place on a new board, ISS will not consider that board in determining if the director is overhoarded.

Shareholder Rights & Defenses

78. Poison pills: What features of a qualifying offer clause are considered to strengthen its effectiveness and what features are considered to weaken its effectiveness?

Attributes of a qualifying offer clause that strengthen its effectiveness as a tool for shareholders include:

- Provision of a material adverse effect/condition ("MAE") clause;
- Reasonable requirements with respect to the length of time an offer is outstanding:
 - Offeror is not required to keep the offer open longer than 60 business days in the absence of an MAE clause or 90 business days if there is an MAE clause, and
 - No more than 15 business days following a price increase or an alternative bid or tender offer);
- Reasonable overall timing requirements with respect to the mechanics of calling a special meeting to vote on redemption of the pill (no longer than 150 business days from the time an offer is made until the time a special meeting is held).

Attributes of a qualifying offer clause that weaken its effectiveness and potentially discourage offers from being made include:

- A requirement that the offer be cash only;
- A provision allowing the company to declare an offer to not be a qualifying offer if the company procures an inadequacy opinion;
- A reverse due diligence requirement; and
- A requirement specifying the level of premium.



Capital/Restructuring

79. Under the Capital Structure Framework, what are ISS' allowable increases?

ISS will apply the relevant allowable increase below to requests to increase common stock that are for general corporate purposes (or to the general corporate purposes portion of a request that also includes a specific need):

- Most companies: 100 percent of existing authorized shares
- Companies with less than 50 percent of existing authorized shares either outstanding or reserved for issuance: **50 percent** of existing authorized shares
- Companies with one- and three-year total shareholder returns (TSRs) in the bottom 10 percent of the U.S. market as of the end of the calendar quarter that is closest to their most recent fiscal year end: **50 percent** of existing authorized shares
- Companies at which both conditions (B and C) above are both present: **25 percent** of existing authorized shares If there is an acquisition, private placement, or similar transaction on the ballot (not to include equity incentive plans), the allowable increase will be the greater of (i) twice the amount needed to support the transactions on the ballot, and (ii) the allowable increase as calculated above.

80. Are my company's one- and three-year TSRs in the bottom 10 percent of the U.S. market?

The reduced allowable increase applies to companies whose one- and three-year TSRs are both below the applicable thresholds below:

Thusa Vasu

Most Recent Fiscal Year End	One-Year TSR	<u>Inree-Year</u> <u>TSR</u>
May 15, 2013 – Aug. 14, 2013	-61.36%	-49.71%
Aug. 15, 2013 – Nov. 14, 2013	-56.76%	-47.27%
Nov. 15, 2013 – Feb. 14, 2014	-56.01%	-50.43%
Feb. 15, 2014 – May 14, 2014	-50.00%	-47.53%

The universe used for the "U.S. market" is the \$C set in Standard & Poor's Research Insight product. To calculate these thresholds, we remove from the set any companies that do not have both one- and three-year TSRs.

81. When does ISS deem a risk of non-approval to be "specific and severe"?

Issuers should disclose any risks associated with shareholders' failure to approve a capitalization proposal in the proxy statement. The types of risks that may influence vote recommendations by virtue of being "specific and severe," <u>if disclosed</u> in the proxy statement, are as follows:

- In or subsequent to the company's most recent 10-K filing, the company's auditor raised substantial doubts about the company's ability to continue as a going concern;
- The company states that there is a risk of imminent bankruptcy or imminent liquidation if shareholders do not approve the increase in authorized capital; or
- A government body has in the past year required the company to increase its capital ratios.

82. When will an issuer's past use of shares drive vote recommendations?

If, within the past three years, the board adopted a poison pill without shareholder approval, repriced or exchanged underwater stock options without shareholder approval, or placed a substantial amount of stock with insiders at prices substantially below market value without shareholder approval, ISS will typically recommend that shareholders vote against the requested increase in authorized capital on the basis of imprudent past use of shares.



83. What disclosure is required to "declaw" preferred stock?

Sample Language:

"The board represents that it will not, without prior stockholder approval, issue or use the preferred stock for any defensive or anti-takeover purpose or for the purpose of implementing any stockholder rights plan."

Social/Environmental Issues

Lobbying Proposals

84. What does ISS look for when reviewing disclosure of a company's lobbying activity board oversight?

ISS reviews company materials to determine if the full board is primarily responsible for exercising oversight of a company's lobbying activities or if a committee of the board has been assigned responsibility for such oversight. The frequency of lobbying activity review is also considered, that is, whether just a general reference of responsibility is made or if a specific frequency of review (such as annually, biannually, or quarterly) is disclosed. ISS also looks for additional details regarding the scope of the board's (or delegated committee's) oversight responsibilities for both direct and indirect lobbying activity; such as reviewing compliance with existing company policies, or ensuring consistency with company values and public policy priorities.

85. What does ISS look for when reviewing a company's indirect lobbying expenditures?

When reviewing company disclosures of indirect lobbying expenditures, which are typically payments to trade associations and other groups, including membership dues used for lobbying purposes, a number of factors are considered. These factors include: (1) whether the company's reported lobbying expenditures are aggregated and provided as a single figure or if the company provides an itemized listing by recipient of its lobbying expenditures; and (2) whether the company comprehensively reports its lobbying expenditures or if information is only provided for the company's "significant" trade association relationships. With respect to the first factor, ISS also notes if the company provides information on the portion of trade association dues that were not tax deductible due to their use for lobbying purposes, and evaluates the level of disclosure on non-dues lobbying expenditures that were provided explicitly to support a trade association's lobbying activities.

86. What else does ISS consider when reviewing lobbying-related proposals?

In addition to the questions above, other factors are taken into consideration when preparing a lobbying-related proposal analysis and determining a vote recommendation. These include a company's disclosure and discussion of relevant lobbying policies and related management roles and oversight. ISS also considers whether the company has been associated with any recent lobbying-related controversies, fines, or litigation. Finally, ISS may also review and incorporate in our analysis and vote recommendation other relevant information per the ISS Global Approach.

Note: The questions and answers in this FAQ document are intended to provide high-level guidance regarding the way in which ISS' Global Research Department will generally analyze certain issues in the context of preparing proxy analyses and vote recommendations for U.S. companies. However, these responses should not be construed as a guarantee as to how ISS' Global Research Department will apply its benchmark policy in any particular situation.